October 3, 2026: German pharmaceutical and life sciences company Bayer has announced plans to invest $2.2 billion in a new pharmaceutical manufacturing site in New Albany, Ohio, as the company expands its manufacturing presence in the United States.
The planned facility is expected to create approximately 600 high-value jobs once operational, while around 1,500 temporary construction jobs are expected during the development of the site.
The project is designed to strengthen Bayer's pharmaceutical production capabilities and support the company's growing portfolio of medicines for patients in the United States and other markets.
New Pharmaceutical Campus in Ohio
Bayer plans to build the new manufacturing campus at the New Albany International Business Park near Columbus, Ohio.
The company describes the project as a state-of-the-art pharmaceutical manufacturing site that will combine advanced production technologies with digital systems and automation.
The facility is planned as a flexible and modular campus, allowing Bayer to expand manufacturing capabilities through multiple production modules.
The first module will focus on drug-substance manufacturing, while a second module will be dedicated to producing finished drug products.
First Production Module Expected in 2031
The first manufacturing module is expected to become operational in 2031.
A second module focused on finished pharmaceutical products is planned to follow in 2034.
The long development timeline reflects the complex engineering, construction, validation and regulatory requirements involved in establishing a modern pharmaceutical manufacturing facility.
Before medicines can be produced commercially at the site, the facility and its manufacturing processes will need to meet applicable quality and regulatory standards.
600 New Jobs Expected
Bayer expects the completed site to employ around 600 people in high-skilled positions.
The jobs are expected to cover areas including pharmaceutical manufacturing, engineering, laboratory operations, technology, maintenance and other specialized functions.
The construction phase is expected to create approximately 1,500 additional jobs on a temporary basis.
The investment is also expected to contribute to the development of Ohio's wider life-sciences and biomanufacturing ecosystem.
Focus on Major Medicine Categories
The new facility is expected to support Bayer's pharmaceutical portfolio in several important therapeutic areas.
These include oncology, cardiovascular medicine and renal care.
Bayer's pharmaceutical business includes medicines used to treat conditions ranging from cardiovascular and kidney diseases to cancer.
The company says the new site will help strengthen its ability to manufacture innovative medicines for patients in the United States and internationally.
Why Bayer Is Expanding in the United States
The United States is an important market for Bayer's pharmaceutical division.
According to the company, more than $7 billion has already been invested in U.S. pharmaceutical research, development and manufacturing during the past five years.
The new Ohio project represents another major investment in that strategy.
Bayer has said that the United States is its fastest-growing pharmaceutical market and that strengthening local production can help the company serve patients and customers more efficiently.
Advanced Automation and Digital Technology
The planned facility will incorporate advanced digital technologies and automation into its manufacturing operations.
Modern pharmaceutical factories increasingly use automated systems to monitor production processes, control manufacturing conditions and maintain consistent product quality.
Bayer's planned campus is also designed around a flexible production model, which could allow manufacturing capacity to be adapted as demand and the company's pharmaceutical portfolio change.
Building a More Resilient Medicine Supply Chain
The investment comes as pharmaceutical companies and governments continue to focus on the resilience of medicine supply chains.
Manufacturing medicines closer to major markets can reduce dependence on long international supply routes and provide additional production capacity.
Bayer says the Ohio facility will complement its existing U.S. pharmaceutical operations and contribute to the reliability of its global product-supply network.
Ohio Expands Its Life-Sciences Sector
The Bayer investment also adds to a growing concentration of life-sciences companies in the New Albany area.
The region has attracted pharmaceutical and healthcare companies and is developing additional training infrastructure for workers entering the biomanufacturing industry.
A new Ohio Life Science Training Center is planned to help prepare workers for careers in advanced pharmaceutical and biotechnology manufacturing.
This could provide a future workforce pipeline for Bayer and other companies operating in the region.
Long-Term Pharmaceutical Manufacturing Strategy
Bayer's new Ohio project is part of a broader effort to expand its pharmaceutical manufacturing and commercial capabilities.
The company is developing medicines across several therapeutic categories and expects the United States to remain an important market for future growth.
The planned facility will therefore serve both as a manufacturing investment and as part of Bayer's longer-term strategy for its pharmaceutical business.
What Happens Next?
The project will now move through the planning, construction and regulatory stages required to establish the new manufacturing campus.
Construction will take place over several years, with the first production module targeted for operation in 2031.
The second module is expected to become operational in 2034.
Once completed, the facility will become another major pharmaceutical manufacturing location for Bayer in the United States.
The $2.2 billion investment highlights the continuing expansion of advanced pharmaceutical manufacturing in the United States and the growing role of automation, digital technology and specialized workforce development in the modern life-sciences industry.
Journalist: Vijay Singh